Hidradenitis Suppurativa in the Pediatric Population
An OMNY Health™ Poster
Givent the limited literature, it is important to understand current characteristics and treatments of pediatric patients with hidradenitis suppurativa (HS).
On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.
Conclusions:
- Results provide insight into characteristics and treatments of pediatric HS within a diverse set of US healthcare setting.
- Acne presented as the most common comorbidity while TC and SAI were the most common forms of treatment prescribed to patients.
- Future analyses would be helpful to determine patient journeys and burden of disease among pediatric HS patients.